• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Gardasil (Human Papillomavirus Quadrivalent Types 6, 11, 16, 18) Recombinant Vaccine

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009

 

Summary View

 

WARNINGS and PRECAUTIONS

  • addition of syncope to the section emphasizes that healthcare providers and consumers should be alert that fainting may occur following vaccination with Gardasil, sometimes resulting in falling and injuries.
  • new information about reports of convulsive syncope, which means fainting associated with seizure-like activity
  • recipients of Gardasil should be observed for 15 minutes after vaccination.  Gardasil recipients should be encouraged to remain seated or lying down for this length of time.